• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area.色素沉着皮肤患者特应性皮炎结局指标的可靠性和有效性：一个灰色地带。
Int J Womens Dermatol. 2015 Aug 6;1(3):150-154. doi: 10.1016/j.ijwd.2015.05.002. eCollection 2015 Aug.
2
A pilot comparison study of four clinician-rated atopic dermatitis severity scales.四种临床医生评估的特应性皮炎严重程度量表的初步比较研究。
Br J Dermatol. 2015 Aug;173(2):488-97. doi: 10.1111/bjd.13846. Epub 2015 Jul 1.
3
Assessment of Intra- and Inter-Rater Reliability of Three Methods for Measuring Atopic Dermatitis Severity: EASI, Objective SCORAD, and IGA.三种测量特应性皮炎严重程度方法的评分者内及评分者间信度评估：湿疹面积及严重程度指数（EASI）、客观SCORAD和医师全面评估（IGA）
Dermatology. 2017;233(1):16-22. doi: 10.1159/000472711. Epub 2017 May 12.
4
Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.特应性皮炎临床体征评估：系统评价和建议。
J Allergy Clin Immunol. 2013 Dec;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008. Epub 2013 Sep 12.
5
A comparison study of clinician-rated atopic dermatitis outcome measures for intermediate- to dark-skinned patients.中重度深色皮肤患者的临床医生评估特应性皮炎结局测量指标的比较研究。
Br J Dermatol. 2017 Apr;176(4):985-992. doi: 10.1111/bjd.15271. Epub 2017 Mar 1.
6
Severity strata for Eczema Area and Severity Index (EASI), modified EASI, Scoring Atopic Dermatitis (SCORAD), objective SCORAD, Atopic Dermatitis Severity Index and body surface area in adolescents and adults with atopic dermatitis.特应性皮炎青少年和成人患者的湿疹面积和严重程度指数（EASI）、改良 EASI、特应性皮炎评分（SCORAD）、客观 SCORAD、特应性皮炎严重程度指数和体表面积严重程度分层。
Br J Dermatol. 2017 Nov;177(5):1316-1321. doi: 10.1111/bjd.15641. Epub 2017 Oct 1.
7
Comparison of patient (POEM), observer (EASI, SASSAD, TIS) and corneometry measures of emollient effectiveness in children with eczema: findings from the COMET feasibility trial.比较患者（POEM）、观察者（EASI、SASSAD、TIS）和角膜测量仪在儿童湿疹中保湿剂有效性的测量结果：来自 COMET 可行性试验的结果。
Br J Dermatol. 2018 Aug;179(2):362-370. doi: 10.1111/bjd.16475. Epub 2018 Jun 7.
8
The Self-administered Eczema Area and Severity Index in children with moderate to severe atopic dermatitis: better estimation of AD body surface area than severity.中重度特应性皮炎患儿的自我管理湿疹面积和严重程度指数：对特应性皮炎体表面积的估计优于严重程度评估。
Pediatr Dermatol. 2010 Sep-Oct;27(5):470-5. doi: 10.1111/j.1525-1470.2010.01285.x. Epub 2010 Aug 26.
9
Mild to moderate atopic dermatitis severity can be reliably assessed using smartphone-photographs taken by the patient at home: A validation study.轻度至中度特应性皮炎严重程度可通过患者在家中使用智能手机拍摄的照片进行可靠评估：一项验证研究。
Skin Res Technol. 2022 Mar;28(2):336-341. doi: 10.1111/srt.13136. Epub 2022 Jan 12.
10
Validation of remote atopic dermatitis severity assessment with the Eczema Area and Severity Ondex in children using caregiver-provided photos and videos.使用照顾者提供的照片和视频，通过湿疹面积和严重程度指数对儿童远程特应性皮炎严重程度评估的验证。
Pediatr Dermatol. 2022 Jul;39(4):547-552. doi: 10.1111/pde.15003. Epub 2022 May 6.

引用本文的文献

1
Efficacy and Safety of Lebrikizumab in Adult and Adolescent Patients with Skin of Color and Moderate-to-Severe Atopic Dermatitis: Results from the Phase IIIb, Open-Label ADmirable Study.乌帕替尼治疗中度至重度特应性皮炎成人和青少年患者的疗效和安全性：IIIb期、开放标签ADmirable研究结果
Am J Clin Dermatol. 2025 Jul 15. doi: 10.1007/s40257-025-00970-8.
2
Beyond the surface: a color-inclusive guide to central line site assessment.深入剖析：中心静脉置管部位评估的全彩指南
Antimicrob Steward Healthc Epidemiol. 2024 Apr 3;4(1):e41. doi: 10.1017/ash.2024.39. eCollection 2024.
3
Phenotypes, endotypes and genotypes of atopic dermatitis and allergy in populations of African ancestry on the continent and diaspora.非洲大陆及散居地非洲裔人群中特应性皮炎和过敏的表型、内型和基因型。
Front Allergy. 2024 Jan 24;4:1203304. doi: 10.3389/falgy.2023.1203304. eCollection 2023.
4
Solving the health disparity of eczema assessment: A role for skin tape soluble protein?解决湿疹评估中的健康差异：皮肤胶带可溶性蛋白的作用？
J Allergy Clin Immunol Glob. 2023 Oct 17;3(1):100180. doi: 10.1016/j.jacig.2023.100180. eCollection 2024 Feb.
5
Remote severity assessment in atopic dermatitis: Validity and reliability of the remote Eczema Area and Severity Index and Self-Administered Eczema Area and Severity Index.特应性皮炎的远程严重程度评估：远程湿疹面积和严重程度指数以及自我管理的湿疹面积和严重程度指数的有效性和可靠性。
JAAD Int. 2023 Aug 28;13:184-191. doi: 10.1016/j.jdin.2023.07.019. eCollection 2023 Dec.
6
Ethnicity, Race and Skin Color: Challenges and Opportunities for Atopic Dermatitis Clinical Trials.种族、肤色与特应性皮炎临床试验：挑战与机遇
J Clin Med. 2023 Jun 1;12(11):3805. doi: 10.3390/jcm12113805.
7
Racial disparities in dermatology.皮肤科的种族差异。
Arch Dermatol Res. 2023 Jul;315(5):1215-1223. doi: 10.1007/s00403-022-02507-z. Epub 2022 Dec 12.
8
Development of High-Quality Artificial Intelligence in Dermatology: Guidelines, Pitfalls, and Potential.皮肤病学中高质量人工智能的发展：指南、陷阱与潜力
JID Innov. 2022 Sep 7;2(6):100157. doi: 10.1016/j.xjidi.2022.100157. eCollection 2022 Nov.
9
Dupilumab Improves Skin Barrier Function in Adults with Atopic Dermatitis: A Prospective Observational Study.度普利尤单抗改善成人特应性皮炎患者的皮肤屏障功能：一项前瞻性观察研究。
J Clin Med. 2022 Jun 10;11(12):3341. doi: 10.3390/jcm11123341.
10
Art of prevention: Atopic dermatitis in women and families of color-prevalence, recognition, and prevention.预防的艺术：有色人种女性及其家庭中的特应性皮炎——患病率、识别与预防
Int J Womens Dermatol. 2022 Mar 29;8(1):e014. doi: 10.1097/JW9.0000000000000014. eCollection 2022 Mar.

本文引用的文献

1
Efficacy of systemic treatments for atopic dermatitis in racial and ethnic minorities in the United States.美国少数族裔中特应性皮炎全身治疗的疗效
JAMA Dermatol. 2014 Nov;150(11):1232-4. doi: 10.1001/jamadermatol.2014.1674.
2
Report from the third international consensus meeting to harmonise core outcome measures for atopic eczema/dermatitis clinical trials (HOME).第三届国际共识会议报告：协调特应性皮炎临床试验的核心结局指标（HOME）
Br J Dermatol. 2014 Dec;171(6):1318-25. doi: 10.1111/bjd.13237. Epub 2014 Nov 14.
3
Atopic dermatitis in different skin types. What is to know?不同皮肤类型中的特应性皮炎。需要了解什么？
J Eur Acad Dermatol Venereol. 2014 May;28 Suppl 3:2-4. doi: 10.1111/jdv.12480.
4
Filaggrin-2 variation is associated with more persistent atopic dermatitis in African American subjects.Filaggrin-2 变异与非裔美国人中更持久的特应性皮炎有关。
J Allergy Clin Immunol. 2014 Mar;133(3):784-9. doi: 10.1016/j.jaci.2013.09.015. Epub 2013 Nov 1.
5
Assessment of clinical signs of atopic dermatitis: a systematic review and recommendation.特应性皮炎临床体征评估：系统评价和建议。
J Allergy Clin Immunol. 2013 Dec;132(6):1337-47. doi: 10.1016/j.jaci.2013.07.008. Epub 2013 Sep 12.
6
Reporting, representation, and subgroup analysis of race and ethnicity in published clinical trials of atopic dermatitis in the United States between 2000 and 2009.2000年至2009年间美国已发表的特应性皮炎临床试验中种族和民族的报告、呈现及亚组分析。
Pediatr Dermatol. 2012 Nov-Dec;29(6):749-55. doi: 10.1111/j.1525-1470.2012.01797.x. Epub 2012 Sep 28.
7
Towards global consensus on outcome measures for atopic eczema research: results of the HOME II meeting.迈向特应性皮炎研究结局指标的全球共识：HOME II 会议的结果。
Allergy. 2012 Sep;67(9):1111-7. doi: 10.1111/j.1398-9995.2012.02874.x. Epub 2012 Jul 30.
8
Investigating international time trends in the incidence and prevalence of atopic eczema 1990-2010: a systematic review of epidemiological studies.调查 1990-2010 年特应性皮炎发病和流行的国际时间趋势：一项流行病学研究的系统回顾。
PLoS One. 2012;7(7):e39803. doi: 10.1371/journal.pone.0039803. Epub 2012 Jul 11.
9
Atopic dermatitis in African American children: addressing unmet needs of a common disease.非裔美国儿童的特应性皮炎：满足一种常见疾病未被满足的需求
Pediatr Dermatol. 2012 Jul-Aug;29(4):395-402. doi: 10.1111/j.1525-1470.2012.01740.x. Epub 2012 Apr 4.
10
Harmonising Outcome Measures for Eczema (HOME). Report from the First International Consensus Meeting (HOME 1), 24 July 2010, Munich, Germany.特应性皮炎结局指标协调（HOME）。第一次国际共识会议（HOME1）报告，2010 年 7 月 24 日，德国慕尼黑。
Br J Dermatol. 2010 Dec;163(6):1166-8. doi: 10.1111/j.1365-2133.2010.10054.x.

色素沉着皮肤患者特应性皮炎结局指标的可靠性和有效性：一个灰色地带。

The reliability and validity of outcome measures for atopic dermatitis in patients with pigmented skin: A grey area.

作者信息

Zhao C Y, Wijayanti A, Doria M C, Harris A G, Jain S V, Legaspi K N, Dlova N C, Law M G, Murrell D F

机构信息

Department of Dermatology, St. George Hospital, Sydney, Australia.

Faculty of Medicine, University of New South Wales, Sydney, Australia.

出版信息

Int J Womens Dermatol. 2015 Aug 6;1(3):150-154. doi: 10.1016/j.ijwd.2015.05.002. eCollection 2015 Aug.

DOI:10.1016/j.ijwd.2015.05.002
PMID:28491979
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5418878/
Abstract

BACKGROUND

Outcome measures for atopic dermatitis (AD) patients with pigmented skin have neither been developed nor validated.

OBJECTIVE

To compare the reliability and validity of four common AD outcome measures in patients with various levels of skin darkness.

METHOD

The inter- and intra-rater reliability and construct validity of the EASI (Eczema Area and Severity Index), objective-SCORing Atopic Dermatitis (oSCORAD), Three Items Severity index (TIS) and Six Areas, Six Sites Atopic Dermatitis (SASSAD) were evaluated in 18 patients of various levels of skin darkness, using their full body photographs, by five trained clinicians.

RESULTS

The inter-rater reliability intraclass coefficient (ICCs) and 95% confidence intervals were poor for highly pigmented patients: EASI -.054(-.200 to .657), oSCORAD -.089(-.206 to .598), TIS -.21(-.24 to .147), SASSAD -.071(-.200 to .631); fair for mildly pigmented patients: EASI .464(.140-.839), oSCORAD .588(.265-.89), TIS.524(.200-.865), SASSAD .41(.045-.775); and fair to good for non-pigmented patients: EASI .64(.330-.908), oSCORAD .586(.263-.889), TIS .403(.09-.809), SASSAD .667(.358-.916). Erythema likely contributed to the inter-rater variability. Construct validity had significant correlations across all measures in non-pigmented patients, but no correlations in highly pigmented patients.

CONCLUSION

AD outcome measures have poor reliability and validity in highly pigmented patients, with variations in erythema perception being a contributor.

摘要

背景

针对色素沉着皮肤的特应性皮炎（AD）患者，尚未开发和验证其疗效评估指标。

目的

比较四种常用的AD疗效评估指标在不同皮肤色素沉着程度患者中的可靠性和有效性。

方法

由五名经过培训的临床医生，根据18名不同皮肤色素沉着程度患者的全身照片，评估湿疹面积及严重程度指数（EASI）、特应性皮炎客观评分（oSCORAD）、三项严重程度指数（TIS）和六区域、六部位特应性皮炎（SASSAD）的评分者间信度、评分者内信度和结构效度。

结果

对于色素沉着严重的患者，评分者间信度组内相关系数（ICC）及95%置信区间较差：EASI为-.054（-.200至.657），oSCORAD为-.089（-.206至.598），TIS为-.21（-.24至.147），SASSAD为-.071（-.200至.631）；对于色素沉着轻度的患者，信度为中等：EASI为.464（.140至.839），oSCORAD为.588（.265至.89），TIS为.524（.200至.865），SASSAD为.41（.045至.775）；对于无色素沉着的患者，信度为中等至良好：EASI为.64（.330至.908），oSCORAD为.586（.263至.889），TIS为.403（.09至.809），SASSAD为.667（.358至.916）。红斑可能导致了评分者间的变异性。在无色素沉着的患者中，所有指标的结构效度均存在显著相关性，但在色素沉着严重的患者中无相关性。

结论

AD疗效评估指标在色素沉着严重的患者中可靠性和有效性较差，红斑感知差异是一个影响因素。